Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 9/2016

Open Access 01-09-2016 | UROSURGERY (J COLLINS, SECTION EDITOR)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage

Authors: Rajan Veeratterapillay, Rakesh Heer, Mark I. Johnson, Raj Persad, Christian Bach

Published in: Current Urology Reports | Issue 9/2016

Login to get access

Abstract

Bladder cancer is the second commonest urinary tract malignancy with 70–80 % being non-muscle invasive (NMIBC) at diagnosis. Patients with high-risk NMIBC (T1/Tis, with high grade/G3, or CIS) represent a challenging group as they are at greater risk of recurrence and progression. Intravesical Bacilli Calmette-Guerin (BCG) is commonly used as first line therapy in this patient group but there is a current worldwide shortage. BCG has been shown to reduce recurrence in high-risk NMIBC and is more effective that other intravesical agents including mitomycin C, epirubicin, interferon-alpha and gemcitabine. Primary cystectomy offers a high change of cure in this cohort (80–90 %) and is a more radical treatment option which patients need to be counselled carefully about. Bladder thermotherapy and electromotive drug administration with mitomycin C are alternative therapies with promising short-term results although long-term follow-up data are lacking.
Literature
1.
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41.CrossRefPubMed
2.
Chavan S, Bray F, Lorter-Tieulent J, et al. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66(1):59–73.CrossRefPubMed
3.
Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumours. UICC International Union Against Cancer. 7th edn. Hoboken, NJ: Wiley-Blackwell; 2009. pp. 262-265.
4.
Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinic pathologic study of 1,515 cases. Am J Clin Pathol. 2010;133(5):788–95.CrossRefPubMed
5.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.CrossRefPubMed
6.
Malmström P-U, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–56.CrossRefPubMed
7.
Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203.CrossRefPubMed
8.
Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–41.CrossRefPubMed
9.
Fernandez-Gomez J, Madero R, Solsona E, Club Urológico Español de Tratamiento Oncológico, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–30.CrossRefPubMed
10.
Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164(3 Pt 1):685–9.CrossRefPubMed
11.
Van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. Urology. 1995;45(4):581–6.CrossRefPubMed
12.
Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol. 2015;67(3):359–60.CrossRefPubMed
13.
Herr HW. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187(2):435–7.CrossRefPubMed
14.
Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014;66(4):677–88.CrossRefPubMed
15.
Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90.CrossRefPubMed
16.
Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–23.CrossRefPubMed
17.
Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5.CrossRefPubMed
18.
Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–70.CrossRefPubMed
19.
Shang PF, Kwong J, Wang ZP, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011;5, CD006885.PubMed
20.
Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–5.CrossRefPubMed
21.
Babjuk M, Burger M, Zigeuner R, Shariat S, Shariat SF, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European Association of Urology. Eur Urol. 2013;64(4):639–53.CrossRefPubMed
22.
Astram A, Khadijah A, Yuri P, Zulfan A, et al. Effective dose and adverse effects of maintenance Bacillus Calmette-Guerin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial. Acta Med Indones. 2014;46(4):298–307.PubMed
23.
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.PubMed
24.
Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161(4):1124–7.CrossRefPubMed
25.
Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle invasive bladder cancer. Eur Urol. 2009;56:247–25.CrossRefPubMed
26.
Di Stasi SM, Vespasiani G, Giannantoni A, et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res. 1997;57:875–80.PubMed
27.
Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 1991;51:3,849–56.
28.
Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–82.CrossRefPubMed
29.
Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43–51.CrossRefPubMed
30.
Khanna O, Cottone R, Son DL, et al. Superficial bladder cancer treated by intravesical bacillus Calmette–Guerin or Adriamycin: multicenter study interim report. Urology. 1997;15(6):520–8.
31.
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462–72.CrossRefPubMed
32.
Shelley MD, Mason MD. Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36:3.
33.
Rintala E, Jauhiainen K, Alfthan O, Hansson E, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol. 1991;20(1):19–25.PubMed
34.
Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith Jr JA, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995;1(3):119–26.CrossRefPubMed
35.
Van Der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173(4):1375–80.CrossRefPubMed
36.
Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30(1):56–9.PubMed
37.
Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol. 1995;153(3):959–63.CrossRefPubMed
38.
Wittlinger M, Rödel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93(2):358–63.CrossRefPubMed
39.
Crezee J, Van Haaren PMA, Westendorp H, et al. Improving locoregional hyperthermia delivery using the 3-D controlled AMC-8 phased array hyperthermia system: a preclinical study. Int J Hyperth. 2009;25(7):581–92.CrossRef
40.
Ogilvie GK, Reynolds HA, Richardson BC, Badger CW, Goss SA, Burdette EC. Performance of a multi-sector ultrasound hyperthermia applicator and control system: in vivo studies. Int J Hyperth. 1990;6(3):697–705.CrossRef
41.
Lammers RJM, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81–93.CrossRefPubMed
42.
Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–8.CrossRefPubMed
43.
Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319–24.CrossRefPubMedPubMedCentral
44.
Giannantoni A, Di Stasi SM, Chancellor MB, et al. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50:1,183–93.CrossRef
45.
Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999;59:4,912–8.
46.
Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;17:1205–9.CrossRef
47.
Martinez-Pineiro J, Jimenez Leon AJ, Martinez-Pineiro Jr L, et al. Bacillus Calmette–Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143(3):502–6.PubMed
48.
Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1, CD009294.PubMed
49.
Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62:1088.CrossRefPubMed
50.
Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175:881.CrossRefPubMed
51.
Juergen E, Gschwend, Retz M, Kuebler H, Autenrieth M. Indications and oncologic outcome of radical cystectomy for urothelial bladder cancer. Eur Urol Suppl. 2010;9(1):10–8.CrossRef
52.
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.PubMed
53.
Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296–9.CrossRefPubMed
54.
Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33–6.CrossRefPubMed
Metadata
Title
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Authors
Rajan Veeratterapillay
Rakesh Heer
Mark I. Johnson
Raj Persad
Christian Bach
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Urology Reports / Issue 9/2016
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0625-z

Other articles of this Issue 9/2016

Current Urology Reports 9/2016 Go to the issue

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy

Men’s Health (A Dabaja, Section Editor)

Role of Abnormal Sperm Morphology in Predicting Pregnancy Outcomes

Case Report

Ct2 Bladder Cancer

Benign Prostatic Hyperplasia (K McVary, Section Editor)

The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery

Men’s Health (A Dabaja, Section Editor)

Peyronie’s Disease: Intralesional Therapy and Surgical Intervention

Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

Mesh Perforation into a Viscus in the Setting of Pelvic Floor Surgery—Presentation and Management